SAM
TXMD icon

Smartleaf Asset Management’s TherapeuticsMD TXMD Stock Holding History

Smartleaf Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35K Hold
601
– – ﹤0.01% 3043
2026
Q1 		$1.2K Hold
601
– – ﹤0.01% 3083
2025
Q4 		$986 Buy
+601
New +$869 ﹤0.01% 3162

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Smartleaf Asset Management's TXMD Position: Q2 2026 in Review

Smartleaf Asset Management held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 601 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

Smartleaf Asset Management first reported a position in TXMD in Q4 2025 and has held it in 3 quarters since. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Smartleaf Asset Management held 601 shares of TherapeuticsMD worth $1.35K as of Q2 2026.
  • Smartleaf Asset Management left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3043 holding.
  • Smartleaf Asset Management first reported a position in TherapeuticsMD in Q4 2025 and has held it in 3 quarters since.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.